BACKGROUND: Trauma is a leading cause of death, and traumatic brain injury is one of the hallmark injuries of current military conflicts. Valproic acid (VPA) administration in high doses (300-400 mg/kg) improves survival in lethal trauma models, but effectiveness of lower doses on survival is unknown. This information is essential for properly designing the upcoming clinical trials. We, therefore, performed the current study to determine the lowest dose at which VPA administration improves survival in a model of lethal injuries. METHODS: Swine were subjected to traumatic brain injury (10-mm cortical impact), 40% blood volume hemorrhage, and multiple trauma (femur fracture, rectus crush, and Grade V liver laceration). After 1 hour of shock, animals were randomized (n = 6/group) to four groups: normal saline (NS) resuscitation; or NS with VPA doses of 150 mg/kg (VPA 150) or 100 mg/kg (VPA 100) administered over 3 hours or 100 mg/kg over 2 hours (VPA 100 over 2 hours). Three hours after shock, packed red blood cells were given, and animals were monitored for another 4 hours. Survival was assessed using Kaplan-Meier and log-rank test. RESULTS: Without resuscitation, all of the injured animals died within 5 hours. Similar survival rates were observed in the NS (17%) and VPA 100 (0%) resuscitation groups. Survival rates in the 100-mg/kg VPA groups were significantly (p < 0.05) better when it was given over 2 hours (67%) compared to 3 hours (0%). 83% of the animals in the VPA 150 group survived, which was significantly higher than the NS and VPA 100 over 3 hours groups (p < 0.05). CONCLUSION: A single dose of VPA (150 mg/kg) significantly improves survival in an otherwise lethal model of multiple injuries. This is a much lower dose than previously shown to have a survival benefit and matches the dose that is tolerated by healthy human subjects with minimal adverse effects. LEVEL OF EVIDENCE: Therapeutic, level V.
BACKGROUND:Trauma is a leading cause of death, and traumatic brain injury is one of the hallmark injuries of current military conflicts. Valproic acid (VPA) administration in high doses (300-400 mg/kg) improves survival in lethal trauma models, but effectiveness of lower doses on survival is unknown. This information is essential for properly designing the upcoming clinical trials. We, therefore, performed the current study to determine the lowest dose at which VPA administration improves survival in a model of lethal injuries. METHODS:Swine were subjected to traumatic brain injury (10-mm cortical impact), 40% blood volume hemorrhage, and multiple trauma (femur fracture, rectus crush, and Grade V liver laceration). After 1 hour of shock, animals were randomized (n = 6/group) to four groups: normal saline (NS) resuscitation; or NS with VPA doses of 150 mg/kg (VPA 150) or 100 mg/kg (VPA 100) administered over 3 hours or 100 mg/kg over 2 hours (VPA 100 over 2 hours). Three hours after shock, packed red blood cells were given, and animals were monitored for another 4 hours. Survival was assessed using Kaplan-Meier and log-rank test. RESULTS: Without resuscitation, all of the injured animals died within 5 hours. Similar survival rates were observed in the NS (17%) and VPA 100 (0%) resuscitation groups. Survival rates in the 100-mg/kg VPA groups were significantly (p < 0.05) better when it was given over 2 hours (67%) compared to 3 hours (0%). 83% of the animals in the VPA 150 group survived, which was significantly higher than the NS and VPA 100 over 3 hours groups (p < 0.05). CONCLUSION: A single dose of VPA (150 mg/kg) significantly improves survival in an otherwise lethal model of multiple injuries. This is a much lower dose than previously shown to have a survival benefit and matches the dose that is tolerated by healthy human subjects with minimal adverse effects. LEVEL OF EVIDENCE: Therapeutic, level V.
Authors: Glenn K Wakam; Ben E Biesterveld; Manjunath P Pai; Michael T Kemp; Rachel L O'Connell; Krishani K Rajanayake; Kiril Chtraklin; Claire A Vercruysse; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2021-11-01 Impact factor: 3.313
Authors: Ben E Biesterveld; Ali Z Siddiqui; Rachel L O'Connell; Henriette Remmer; Aaron M Williams; Alizeh Shamshad; William M Smith; Michael T Kemp; Glenn K Wakam; Hasan B Alam Journal: J Surg Res Date: 2021-05-20 Impact factor: 2.417
Authors: Rachel L O'Connell; Glenn K Wakam; Ali Siddiqui; Aaron M Williams; Nathan Graham; Michael T Kemp; Kiril Chtraklin; Umar F Bhatti; Alizeh Shamshad; Yongqing Li; Hasan B Alam; Ben E Biesterveld Journal: Trauma Surg Acute Care Open Date: 2021-02-01
Authors: Ben E Biesterveld; Rachel O'Connell; Michael T Kemp; Glenn K Wakam; Aaron M Williams; Manjunath P Pai; Hasan B Alam Journal: Trauma Surg Acute Care Open Date: 2021-03-17
Authors: Luke Pumiglia; Aaron M Williams; Michael T Kemp; Glenn K Wakam; Hasan B Alam; Ben E Biesterveld Journal: Trauma Surg Acute Care Open Date: 2021-03-24
Authors: Ben E Biesterveld; Luke Pumiglia; Ariella Iancu; Alizeh A Shamshad; Henriette A Remmer; Ali Z Siddiqui; Rachel L O'Connell; Glenn K Wakam; Michael T Kemp; Aaron M Williams; Manjunath P Pai; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2020-12 Impact factor: 3.697
Authors: Cindy H Hsu; Mohamad H Tiba; Brendan M McCracken; Carmen I Colmenero; Zachary Pickell; Danielle C Leander; Anne M Weitzel; Sarita Raghunayakula; Jinhui Liao; Tulasi Jinka; Brandon C Cummings; Manjunath P Pai; Hasan B Alam; Kevin R Ward; Thomas H Sanderson; Robert W Neumar Journal: Resusc Plus Date: 2020-06-01